A novel antibody-KSP inhibitor conjugate improves KSP inhibitor efficacy in vitro and in vivo

Shifting the Antibody–Drug Conjugate Paradigm: A Trastuzumab-Gold-Based Conjugate Demonstrates High Efficacy against Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Mouse Model

“…These doses were selected based on MTD studies with an anti-HER2 antibody and anti-HER2-based ADCs as well as doses for MTD studies for auranofin and other gold­(I)-phosphane compounds when dosed daily or every other day. Since our study was designed to assess the toxicity of ADCs which are typically dosed weekly, ,, these treatment doses and regimen were selected. Mice were intravenously injected with each dose of the drug once a week for 4 weeks.…”